Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure ... effect on the kidney in type 2 diabetes, but DAPA-CKD was the first large-scale trial to test ...

The study offers promising news for people with type 2 diabetes. By using SGLT2 inhibitors, they may be able to lower their ...

The role of the kidney in blood glucose-level regulation was until recently underestimated. Renal gluconeogenesis, renal glucose uptake and tubular glucose reabsorption are the three ways of renal ...

Opens in a new tab or window Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors ... kidney disease, and extremely robust randomized data in heart ...

Starting SGLT2 inhibitors led to a lower risk of eGFR decline ... cohort study. Diabetes is a “major contributor to the rising global burden of chronic kidney disease associated with significant ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure ... was done in patients with type 2 diabetes, mostly because canagliflozin ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Individual SGLT2 inhibitors ... SGLT2 inhibitors for prevention of cardiovascular events in patients with diabetes and in kidney disease, and extremely robust randomized data in heart failure ...